摘要
目的观察华通胶间充质干细胞(WJ-MHCs)移植对心肌梗死后心力衰竭的疗效。方法选择解放军303医院74例心肌梗死后心力衰竭的患者随机分为治疗组(37例)与对照组(37例),对照组只进行常规药物治疗,治疗组在常规药物治疗的基础上进行WJ-MHCs移植。检测各组治疗前及治疗后2 w及第2个月外周血浆N末端B型利钠肽原(NT-proBNP)水平,用心脏超声检测左室心功能指标,并记录严重不良临床事件。结果治疗及随访期间两组临床不良事件发生率差异无统计学意义。治疗后第2 w及第2个月,两组NT-proBNP较术前均有改善,但治疗组较对照组改善更显著(P<0.05);治疗组治疗后第2个月LVEDV较治疗前显著减小(P<0.05),其余左室心功能指标变化差异无统计学意义,而对照组各项指标治疗前后变化无统计学意义。结论 WJ-MHCs移植治疗心肌梗死后心力衰竭安全有效,可以显著降低患者的NT-proBNP水平。
Objective To observe the therapeutic effects of human umbilical cord Wharton＇s jelly mesenchymal stem cells（ WJ-MSC） transplantation on heart failure of acute myocardial infarction. Methods 74 cases with heart failure of acute myocardial infarction in Hospital 303 of PLA were randomly divided into 2 groups： treatment group and control group,37 in each. Drug therapy was applied to patients in both groups,while WJ-MHCs transplantation was added to patients in treatment group. The detections were made to plasma NT-proBNP in the peripheral blood before treatment,2 weeks and 2 months after treatment; and left ventricular function was evaluated by ultrasound; the severe adverse clinical events were recorded. Results The occurrence of adverse clinical events in treatment and follow-up period in the 2 groups was of no statistical difference; NT-proBNP of the patients in both groups 2 weeks and 2months after treatment was more improved than that before treatment,while the improvement in treatment group was more obvious than that in control group（ P〈0. 05）; LVEDV in treatment group 2 months after treatment decreased much more than that before treatment（ P〈0.05）,and the changes of other index of left ventricular function were of no statistical significance; the index before and after treatment in control group were of no statistical changes. Conclusions WJ-MHCs transplantation is safe and effective in treating heart failure of acute myocardial infarction and can greatly decrease the level of NT-proBNP of the patients.
出处
《西南国防医药》
CAS
2014年第5期483-486,共4页
Medical Journal of National Defending Forces in Southwest China
关键词
间充质干细胞
心肌梗死
心力衰竭
细胞移植
mesenchymal stem cells
myocardial infarction
heart failure
cell transplantation
